What's Happening?
Merck, in collaboration with its Chinese partner Kelun-Biotech, has validated the use of a TROP2 antibody-drug conjugate (ADC) in combination with the immunotherapy drug Keytruda for treating first-line lung cancer. This development was revealed through
data from the Phase 3 OptiTROP-Lung05 study, which involved 413 Chinese patients with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific gene mutations. The study demonstrated that the combination treatment led to a 70% objective response rate (ORR) and significantly improved progression-free survival (PFS) compared to a placebo group that received only Keytruda. The median PFS for the combination treatment had not been reached at the 10.5-month cutoff, while the Keytruda-only group had a PFS of 5.7 months. Overall survival data is still immature, but trends are positive. This marks the second positive outcome for the ADC this week, following Merck's announcement of improved survival rates in endometrial cancer patients.
Why It's Important?
The validation of the TROP2-Keytruda combination represents a potential new treatment paradigm for lung cancer, a field with significant competition. The results are particularly promising given the high objective response rate and improved progression-free survival, which could position this combination as a superior option compared to existing treatments. This development is crucial for Merck as it seeks to maintain growth through the Keytruda loss of exclusivity period. The success of this combination could also influence the broader strategy of using TROP2 ADCs in combination with immunotherapies for other cancers. The positive results may drive investor confidence and provide a competitive edge over other pharmaceutical companies developing similar treatments.
What's Next?
Further details on the study will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, which is the largest gathering of oncologists in the U.S. This presentation will delve deeper into the potential of the ADC-Keytruda combination. The results may prompt further clinical trials and regulatory discussions to expand the use of this treatment combination. Additionally, Merck's partnership with Kelun, which includes a $9.3 billion licensing deal, may lead to further developments in ADC programs, potentially expanding their application to other cancer types.
